We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Genetic Links Uncovered Between Psychotic Experiences

By LabMedica International staff writers
Posted on 09 Oct 2019
Psychotic experiences, such as hallucinations and delusions, are features of psychiatric disorders, such as schizophrenia, but they are also reported by approximately 5% to 10% of the general population.

Studying the genetic causes of psychotic experiences in the general population, and its association with the genetic causes of other disorders, may increase the understanding of their pathologic significance. More...
There are shared genetic connections between psychotic experiences and conditions on the psychotic spectrum like schizophrenia, but also with conditions like major depressive disorder and autism spectrum disorder.

A team of scientists working with Cardiff University (Cardiff, UK) analyzed data from the UK Biobank to tease out whether the genetic liability for having a psychotic experience overlaps with that of neuropsychiatric diseases. The team included in their analysis individuals diagnosed with a neuropsychiatric condition, and they had a sample of 7,803 individuals who reported experiencing at least one psychotic experience. The 147,461 individuals who reported no such experience served as the control group.

Through a genome-wide association (GWAS) study of any psychotic experience, the scientists identified two variants, an intronic variant in Ankyrin-3 (ANK3) and an intergenic variant rs10994278. ANK3 encodes ankyrin-G, a protein that regulates the assembly of voltage-gated sodium channels and is needed for normal synaptic function. ANK3, the team noted, has also been tied to bipolar disorder. A second GWAS limited to the 2,143 individuals who rated their psychotic experiences to be distressing identified two additional variants, one in an intron of cannabinoid receptor 2 (CNR2) and an intergenic variant rs3849810. CNR2 encodes CB2, one of the two well-known cannabinoid receptors. A third GWAS of the 3,337 individuals who reported multiple psychotic experiences did not turn up any additional loci.

The authors concluded that in the largest GWAS of psychotic experiences from the population-based UK Biobank sample, they found support for a shared genetic liability between psychotic experiences and several psychiatric disorders including schizophrenia, major depressive disorder, bipolar disorder, and neurodevelopmental disorders, indicating that psychotic experiences are not specifically associated with schizophrenia, but rather with a general risk for mental health disorders. The study was published September 25, 2019, in the journal JAMA Psychiatry.

Related Links:
Cardiff University


New
Gold Member
Aspiration System
VACUSAFE
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
New
Automated Clinical Chemistry Analyzer
Envoy 500+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Plasma pTau217 testing can predict future amyloid accumulation and cognitive decline in cognitively healthy older adults (photo courtesy of Shutterstock)

Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms

Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read more

Industry

view channel
Image: The GenoPredict assay from Predicta Biosciences is available to Tempus Life Sciences partners to support exploratory research and clinical development programs (photo courtesy of Shutterstock)

Partnership Expands Ultrasensitive WGS Assay for for Hematologic Malignancies and MRD Monitoring

Tempus AI and Predicta Biosciences announced the commercial expansion of a co-branded whole‑genome sequencing assay GenoPredicta, which is intended for comprehensive genomic characterization of hematologic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.